Moderna, Inc. (MRNA)
Nasdaq · Healthcare · Biotechnology
$203.21+6.95%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $81.1B
- 52-week range
- $22.28 – $208.90
- 52-week change
- +589.94%
- EPS (trailing)
- −$7.98
- Analyst rating
- 2.8 Hold
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $1.9B (−39.93%)
- Net income
- −$2.8B
- Operating margin
- −158.1%
- Diluted EPS
- −$7.26
- Free cash flow
- −$2.1B
From the company’s annual report on SEC EDGAR.
About Moderna, Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc.
Headquarters: Cambridge, United States · 4,700 employees · modernatx.com